Pulmonal Bacillus Calmette-Guerin Infection 24 Months after Intravesical BCG Installation
Abstract
BCG (Bacillus Calmette-Guérin) immunotherapy is a method which is an emerging form of cancer treatment. BCG attaches to the bladder wall and stimulates an immune response to destroy the cancer cells. Complications of BCG therapy are due to reactivated infection or a hypersensitivity reaction and thus may be treated with antimycobacterial agents, corticosteroids, or both. BCG therapy instillations should also be stopped if complications occur during the treatment period. We present a case wherein a subject sufferef from a disseminated BCG infection 2 years after BCG instillation.
Downloads
References
Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147(3):596-600.
Elkabani M, Greene JN, Vincent AL, VanHook S, Sandin RL. Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer. Cancer Control. 2000;7(5):476-81.
Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol. 2006;44(12):4498-510.
Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother. 2009;53(1):316-8.
Copyright (c) 2022 David Jones et al.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
